Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome


Por: Petersen, ME, Rafii, MS, Zhang, F, Hall, J, Julovich, D, Ances, BM, Schupf, N, Krinsky-McHale, SJ, Mapstone, M, Silverman, W, Lott, I, Klunk, W, Head, E, Christian, B, Foroud, T, Lai, F, Rosas, HD, Zaman, S, Wang, MC, Tycko, B, Lee, JH, Handen, B, Hartley, S, Fortea, J, O'Bryant, S, Alzheimers Biomarker Consortium-Do

Publicada: 1 ene 2021
Resumen:
Background: The need for diagnostic biomarkers of cognitive decline is particularly important among aging adults with Down syndrome (DS). Growing empirical support has identified the utility of plasma derived biomarkers among neurotypical adults with mild cognitive impairment (MCI) and Alzheimer's disease (AD); however, the application of such biomarkers has been limited among the DS population. Objective: This study aimed to investigate the cross-sectional diagnostic performance of plasma neurofilament light chain (Nf-L) and total-tau, individually and in combination among a cohort of DS adults. Methods: Plasma samples were analyzed from n = 305 (n = 225 cognitively stable (CS); n = 44 MCI-DS; n = 36 DS-AD) participants enrolled in the Alzheimer's Biomarker Consortium - Down Syndrome. Results: In distinguishing DS-AD participants from CS, Nf-L alone produced an AUC of 90%, total-tau alone reached 74%, and combined reached an AUC of 86%. When age and gender were included, AUC increased to 93%. Higher values of Nf-L, total-tau, and age were all shown to be associated with increased risk for DS-AD. When distinguishing MCI-DS participants from CS, Nf-L alone produced an AUC of 65%, while total-tau alone reached 56%. A combined model with Nf-L, total-tau, age, and gender produced an AUC of 87%. Both higher values in age and total-tau were found to increase risk for MCI-DS; Nf-L levels were not associated with increased risk for MCI-DS. Conclusion: Advanced assay techniques make total-tau and particularly Nf-L useful biomarkers of both AD pathology and clinical status in DS and have the potential to serve as outcome measures in clinical trials for future disease-modifying drugs.

Filiaciones:
Petersen, ME:
 Univ North Texas, Dept Family Med, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

 Univ North Texas, Inst Translat Res, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

Rafii, MS:
 Univ Southern Calif, Keck Sch Med, Alzheimers Therapeut Res Inst ATRI, San Diego, CA USA

Zhang, F:
 Univ North Texas, Dept Family Med, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

 Univ North Texas, Inst Translat Res, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

Hall, J:
 Univ North Texas, Inst Translat Res, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

 Univ North Texas, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX 76107 USA

Julovich, D:
 Univ North Texas, Inst Translat Res, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

 Univ North Texas, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX 76107 USA

Ances, BM:
 Washington Univ, Sch Med St Louis, Ctr Adv Med Neurosci, St Louis, MO 63110 USA

Schupf, N:
 Columbia Univ, Taub Inst Res Alzheimers Dis, Irving Med Ctr, New York, NY USA

 Columbia Univ, Aging Brain GH Sergievsky Ctr, Irving Med Ctr, New York, NY USA

 Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA

 Columbia Univ, Dept Neurol, Irving Med Ctr, Neurol Inst, New York, NY USA

 Columbia Univ, Dept Psychiat, Med Ctr, New York, NY USA

Krinsky-McHale, SJ:
 NYS Inst Basic Res Dev Disabil, Dept Psychol, Staten Isl, NY USA

Mapstone, M:
 Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA

Silverman, W:
 Univ Calif Irvine, Dept Pediat, Sch Med, Orange, CA 92668 USA

Lott, I:
 Univ Calif Irvine, Dept Pediat, Sch Med, Orange, CA 92668 USA

Klunk, W:
 Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA

Head, E:
 Univ Calif Irvine, Dept Pathol, Irvine, CA 92717 USA

Christian, B:
 Univ Wisconsin, Dept Med Phys & Psychiat, Madison, WI USA

Foroud, T:
 Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA

Lai, F:
 Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA

Rosas, HD:
 Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA

 Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA

Zaman, S:
 Univ Cambridge, Sch Clin Med, Dept Psychiat, Cambridge, England

 Cambridgeshire & Peterborough NHS Fdn Trust, Fulbourn Hosp, Cambridge, England

Wang, MC:
 Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA

Tycko, B:
 Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA

Lee, JH:
 Columbia Univ, Taub Inst Res Alzheimers Dis, Irving Med Ctr, New York, NY USA

 Columbia Univ, Aging Brain GH Sergievsky Ctr, Irving Med Ctr, New York, NY USA

Handen, B:
 Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA

Hartley, S:
 Univ Wisconsin, Sch Human Ecol, Madison, WI USA

 Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA

Fortea, J:
 Fundacio Catalana Sindrome, Barcelona Med Ctr, Barcelona, Spain

 Univ Autonoma Barcelona, Dept Neurol, St Pau Memory Unit, Hosp Santa Creu & St Pau,Biomed Res Inst St Pau, Barcelona, Spain

O'Bryant, S:
 Univ North Texas, Inst Translat Res, Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA

 Univ North Texas, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX 76107 USA
ISSN: 13872877
Editorial
IOS PRESS, NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 79 Número: 2
Páginas: 671-681
WOS Id: 000611560100018
ID de PubMed: 33337378
imagen Green Accepted

MÉTRICAS